Correlation of soluble interleukin-2 receptor levels with severity of chronic hepatitis C virus liver injury and development of hepatocellular cancer

Surgery ◽  
1996 ◽  
Vol 120 (1) ◽  
pp. 100-105 ◽  
Author(s):  
Francesco Izzo ◽  
Steven Curley ◽  
Patrizia Maio ◽  
Enrico Leonardi ◽  
Luca Imparato ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Injury ◽  
Chronic Hepatitis C ◽  
Interleukin 2 ◽  
Hepatocellular Cancer ◽  
Interleukin 2 Receptor ◽  
Chronic Hepatitis C Virus ◽  
Soluble Interleukin 2 Receptor

New treatment options of chronic hepatitis C virus infection

2011 ◽  
Vol 152 (22) ◽  
pp. 887-897 ◽  
Author(s):  
Béla Hunyady
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Rapid Development ◽  
Treatment Options ◽  
Treatment Success ◽  
Hepatocellular Cancer ◽  
Hepatic Decompensation ◽  
Chronic Hepatitis C Virus

Chronic hepatitis C virus (HCV) infection is the major etiology and the reason of chronic liver disease, liver cirrhosis, hepatic decompensation, hepatocellular cancer and liver transplantation. Less than half of patients with HCV-related chronic hepatitis achieve sustained viral clearance with current pegylated interferon and ribavirin (P+R) combination therapy. Due to the insufficient treatment success, an extended search for new, direct acting anti-HCV agents (DAAs) is ongoing, already leading to submissions of applications for marketing authorization of the protease-inhibitors boceprevir and telaprevir. Both are effective only in triple combinations with P+R. Studies demonstrate a 50% success rate advantage for triple therapies above current standards. In addition, treatment duration can be shortened, and half of the patients who failed previous therapy with P+R can be cured with triple therapies. A major concern with new DAAs is rapid development of DAA-resistant viral mutants, a reason as well as a consequence of insufficient triple therapy. Clinical studies with boceprevir and telaprevir are reviewed in this paper. Orv. Hetil., 2011, 152, 887–897.

Prognostic value of the soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alfa

1999 ◽  
Vol 31 (4) ◽  
pp. 612-617 ◽  
Author(s):  
Sylvie Naveau ◽  
Axel Balian ◽  
Françoise Degos ◽  
Véronique Daurat ◽  
Sylvie Chevret ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Prognostic Value ◽  
Interleukin 2 ◽  
Interferon Alfa ◽  
Interleukin 2 Receptor ◽  
Soluble Interleukin 2 Receptor

Serum levels of soluble interleukin-2 receptors and effects of interferon-α for patients with chronic hepatitis C virus

1995 ◽  
Vol 40 (8) ◽  
pp. 1837-1841 ◽  
Author(s):  
Jun Hayashi ◽  
Yasuhiro Kishihara ◽  
Kouzaburo Yamaji ◽  
Eriko Yoshimura ◽  
Misako Ohmiya ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Interleukin 2 ◽  
Serum Levels ◽  
Interferon Α ◽  
Chronic Hepatitis C Virus

scholarly journals The Risk of Acute Liver Injury With Statin Use in Chronic Hepatitis C Virus Infection

2016 ◽  
Vol 3 (suppl_1) ◽  
Author(s):  
Dana Byrne ◽  
Janet P. Tate ◽  
Kimberly Forde ◽  
Jay R. Kostman ◽  
Jason Roy ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Injury ◽  
Virus Infection ◽  
Chronic Hepatitis C ◽  
Acute Liver Injury ◽  
Hepatitis C Virus Infection ◽  
Chronic Hepatitis C Virus ◽  
Statin Use
Sign in / Sign up

Export Citation Format

Share Document